Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India.
Arch Biochem Biophys. 2010 Aug 15;500(2):196-202. doi: 10.1016/j.abb.2010.05.026. Epub 2010 May 31.
Three COX-2-specific non-steroidal anti-inflammatory drugs (NSAIDs), etoricoxib, parecoxib, and nimesulide are widely prescribed against inflammatory conditions. However, their long term administration leads to severe conditions of cardiovascular complications and gastric ulceration. In order to minimize these side effects, C-terminal half (C-lobe) of colostrum protein lactoferrin has been indicated to be useful if co-administered with NSAIDs. Lactoferrin is an 80kDa glycoprotein with two similar halves designated as N- and C-lobes. Since NSAID-binding site is located in the C-terminal half of lactoferrin, C-lobe was prepared from lactoferrin by limited proteolysis using proteinase K. The incubation of lactoferrin with serine proteases for extended periods showed that N-lobe was completely digested but C-lobe was resistant for more than 72h indicating its long half life in the animal gut. The solution studies have shown that COX-2-specific NSAIDs bind to C-lobe with binding constants ranging from 10(-4) to 10(-5)M showing significant affinities for sequestering these compounds. In order to understand the mode of binding and sequestering properties, the complexes of C-lobe with all these three compounds, etoricoxib, parecoxib, and nimesulide were prepared and the structures of their complexes with C-lobe were determined at 2.2, 2.9, and 2.7A resolutions, respectively. The analysis of the structures of complexes of C-lobe with NSAIDs clearly show that all the three compounds bind firmly at the same ligand-binding site in the C-lobe revealing the details of the interactions between C-lobe and NSAIDs. The mode of binding of COX-2-specific NSAIDs to C-lobe is similar to that of the binding of COX-2 non-specific NSAIDs to C-lobe.
三种 COX-2 特异性非甾体抗炎药(NSAIDs),依托考昔、帕瑞昔布和尼美舒利,被广泛用于治疗炎症性疾病。然而,长期使用这些药物会导致严重的心血管并发症和胃溃疡。为了最小化这些副作用,如果与 NSAIDs 一起使用,乳球蛋白 C 端半胱氨酸(C- lobe)已被证明是有用的。乳铁蛋白是一种 80kDa 的糖蛋白,由两个相似的半胱氨酸称为 N-和 C- lobe 组成。由于 NSAID 结合位点位于乳铁蛋白的 C 端半胱氨酸,因此通过蛋白酶 K 进行有限蛋白水解从乳铁蛋白中制备 C- lobe。乳铁蛋白与丝氨酸蛋白酶孵育延长时间后,发现 N- lobe 完全被消化,但 C- lobe 在超过 72h 时仍保持抵抗性,表明其在动物肠道中的半衰期较长。溶液研究表明,COX-2 特异性 NSAIDs 与 C- lobe 的结合常数范围从 10(-4)到 10(-5)M,显示出对这些化合物的显著亲和力。为了了解结合模式和隔离特性,制备了 C- lobe 与所有三种化合物(依托考昔、帕瑞昔布和尼美舒利)的复合物,并分别在 2.2、2.9 和 2.7Å分辨率下确定了它们与 C- lobe 的复合物结构。对 C- lobe 与 NSAIDs 复合物结构的分析清楚地表明,所有三种化合物都牢固地结合在 C- lobe 的相同配体结合位点,揭示了 C- lobe 与 NSAIDs 之间相互作用的细节。COX-2 特异性 NSAIDs 与 C- lobe 的结合模式与 COX-2 非特异性 NSAIDs 与 C- lobe 的结合模式相似。